Hot spots about target therapy of metastasis colorectal cancer on the 2013 ASCO conference

On the 2013 ASCO conference,there were three important clinical study results released in which involved the hot spots of metastasis colorectal cancer,such as optimization of targeted drug therapy,the best mode of treatment and curative effect prediction.The FIRE3 study failed to make a clear conclusion on the comparison of the first-line drug cetuximab and bevacizumab in the treatment of the wild type KRAS metastatic colorectal cancer.CARIO3 research supported bevacizumab plus capecitabine as a new mode of chemotherapy for colorectal cancer.The follow-up data from the PRIME study and other clinical research results showed that NRAS,BRAF and PIK3CA gene mutation might be a negative predictors of the EGFR monoclonal antibody effectiveness,except KRAS.